NEW YORK, Nov. 07, 2017 /PRNewswire/ -- If you want a Stock Review on MDCO, MNTA, DPLO, or ZTS then come over to http://dailystocktracker.com/register/and sign up for your free customized report. Pre-market today, DailyStockTracker.com monitors the following equities: The Medicines Co. (NASDAQ: MDCO), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Diplomat Pharmacy Inc. (NYSE: DPLO), and Zoetis Inc.
Medicines Co.Parsippany, New Jersey-based The Medicines Co.'s stock finished Monday's session 1.14% higher at $30.07 with a total trading volume of 930,756 shares. Shares of the Company, which provides medicines for patients in acute and intensive care hospitals worldwide, are trading below their 50-day moving average by 13.76%. The stock has a Relative Strength Index (RSI) of 35.51.
On October 24th, 2017, research firm Guggenheim initiated a 'Buy' rating on the Company's stock, with a target price of $45 per share.
On November 06th, 2017, Medicines and Alnylam Pharmaceuticals, Inc. announced the initiation of the Phase-III clinical program for inclisiran, with the commencement of patient dosing on November 01st, 2017 in the ORION-11 trial, a Phase-III study of inclisiran versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), or ASCVD-risk equivalents, and elevated LDL-cholesterol (LDL-C) despite maximum tolerated doses of LDL-C lowering therapies. Your complete research report on MDCO can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=MDCO
Momenta PharmaceuticalsShares in Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc. jumped 4.92%, ending yesterday's session at $13.85 with a total trading volume of 701,457 shares. The stock has gained 6.95% in the past month. The Company's shares are trading 10.93% below their 50-day moving average. Moreover, shares of the Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 46.58.
On November 01st, 2017, Momenta Pharma and Mylan N.V. announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic endpoints in the Phase-1 study to compare the pharmacokinetics, safety, and immunogenicity of M834 to US- and EU-sourced ORENCIA in normal healthy volunteers. The duo continues to gather and analyze these data to inform next steps for the program. A free report on MNTA is just a click away at: http://dailystocktracker.com/registration/?symbol=MNTA
Diplomat PharmacyOn Monday, Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock climbed 0.14%, to close the day at $20.87. A total volume of 760,170 shares was traded, which was above their three months average volume of 531,560 shares. The Company's shares have advanced 25.72% in the previous three months and 65.63% on an YTD basis. The stock is trading 4.89% and 24.26% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 54.88.
On October 30th, 2017, Diplomat Pharmacy has hired Robyn Peters as executive vice president of sales and payor strategies. As a member of the Company's executive leadership team, Peters will oversee payor and business development strategies as well as sales and pharma account management. Sign up for your complimentary research report on DPLO at: http://dailystocktracker.com/registration/?symbol=DPLO
ZoetisShares in Parsippany, New Jersey headquartered Zoetis Inc. ended the day 1.48% higher at $69.71. A total volume of 3.88 million shares was traded, which was above their three months average volume of 2.31 million shares. The stock has gained 9.35% in the last one month, 16.18% in the previous three months, and 30.23% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 8.45% and 16.79%, respectively. Furthermore, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 76.03.
On November 02nd, 2017, Zoetis reported its financial results for Q3 2017 and raised its full year guidance for revenue and net income. For Q3 2017, revenue was $1.3 billion, and net income was $298 million. For the full year 2017, the Company raised its guidance for revenue of between $5.225 billion to $5.275 billion; diluted EPS of between $2.16 to $2.23 per share; and adjusted diluted EPS of between $2.34 to $2.39 per share. Register for free on DailyStockTracker.com and download the latest research report on ZTS at: http://dailystocktracker.com/registration/?symbol=ZTS
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/generic-drugs-stock-performance-review--medicines-co-momenta-pharma-diplomat-pharmacy-and-zoetis-300550760.html
Subscribe to our Free Newsletters!
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...
Bronchopulmonary dysplasia or chronic lung disease of infancy is seen in premature and low birth ...
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...View All